VRTX Stock Analysis: Vertex Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 138.693m USD | 12M Return: 24% | US92532F1003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 785M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Vertex Pharmaceuticals (VRTX) is a large-cap U.S. biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It develops and commercializes specialty medicines targeting the underlying causes of serious diseases, with a commercial portfolio anchored by its cystic fibrosis (CF) franchise-including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The company is also expanding into adjacent specialty areas such as sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and various rare genetic and endocrine disorders through both approved products (CASGEVY, JOURNAVX) and a pipeline of clinical-stage candidates in kidney disease, Type 1 diabetes, myotonic dystrophy, and polycystic kidney disease.
Vertex operates with a business model typical of high-growth specialty biotech firms: heavy investment in R&D to advance a pipeline of disease-modifying therapies, premium pricing for orphan and specialty indications, and reliance on collaborations and licensing deals to extend its scientific capabilities-an example being its strategic partnership with AbCellera Biologics to co-develop multispecific T-cell engagers for autoimmune diseases. Products are sold through specialty pharmacies, distributors, wholesalers, and institutional channels, consistent with the distribution patterns common among rare-disease biopharmaceutical companies.
- TRIKAFTA patent expiry threatens core cystic fibrosis revenue base
- CASGEVY sickle cell launch drives new franchise growth
- JOURNAVX acute pain approval expands non-CF revenue streams
| Net Income: 3.98b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -3.64 > 1.0 |
| NWC/Revenue: 51.48% < 20% (prev 51.98%; Δ -0.51% < -1%) |
| CFO/TA 0.11 > 3% & CFO 3.69b > Net Income 3.98b |
| Net Debt (2.16b) to EBITDA (5.04b): 0.43 < 3 |
| Current Ratio: 2.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (255.2m) vs 12m ago -0.93% < -2% |
| Gross Margin: 85.57% > 18% (prev 86.28%; Δ -0.71% > 0.5%) |
| Asset Turnover: 45.10% > 50% (prev 47.15%; Δ -2.05% > 0%) |
| Interest Coverage Ratio: 360.8 > 6 (EBIT TTM 4.80b / Interest Expense TTM 13.3m) |
| A: 0.20 (Total Current Assets 11.7b - Total Current Liabilities 5.00b) / Total Assets 32.7b |
| B: 0.50 (Retained Earnings 16.3b / Total Assets 32.7b) |
| C: 0.17 (EBIT TTM 4.80b / Avg Total Assets 28.8b) |
| D: 1.77 (Book Value of Equity 20.9b / Total Liabilities 11.8b) |
| Altman-Z'' = 5.94 = AAA |
| DSRI: 1.07 (Receivables 2.31b/1.95b, Revenue 13.0b/11.7b) |
| GMI: 1.01 (GM 86.28% / 85.57%) |
| AQI: 1.19 (AQ_t 0.54 / AQ_t-1 0.45) |
| SGI: 1.11 (Revenue 13.0b / 11.7b) |
| TATA: 0.01 (NI 3.98b - CFO 3.69b) / TA 32.7b) |
| Beneish M = -2.77 (Cap -4..+1) = A |
As of November 15, 2026, the stock is trading at USD 538.60 with a total of 750,525 shares traded. Over the past week, the price has changed by -1.55%, over one month by +11.00%, over three months by +4.29% and over the past year by +23.95%.
Current recommended Stop Loss: 518.40 (which is 3.8% or 1.3 ATR below the current price).
Vertex Pharmaceuticals has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy VRTX.
- StrongBuy: 20
- Buy: 6
- Hold: 4
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 595.4 | 10.5% |
P/E Trailing = 35.2014
P/E Forward = 26.5957
P/S = 10.7085
P/B = 6.6441
P/EG = 2.3795
Revenue TTM = 13.0b USD
EBIT TTM = 4.80b USD
EBITDA TTM = 5.04b USD
Long Term Debt = 3.50b USD (from longTermDebt, last quarter)
Short Term Debt = 999.6m USD (from shortTermDebt, last quarter)
Debt = 8.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.98b
Net Debt = 2.16b USD (calculated: Debt 8.46b - CCE 6.30b)
Enterprise Value = 141b USD (139b + Debt 8.46b - CCE 6.30b)
Interest Coverage Ratio = 360.8 (Ebit TTM 4.80b / Interest Expense TTM 13.3m)
EV/FCF = 43.98x (Enterprise Value 141b / FCF TTM 3.20b)
FCF Yield = 2.27% (FCF TTM 3.20b / Enterprise Value 141b)
FCF Margin = 24.65% (FCF TTM 3.20b / Revenue TTM 13.0b)
Net Margin = 30.61% (Net Income TTM 3.98b / Revenue TTM 13.0b)
Gross Margin = 85.57% ((Revenue TTM 13.0b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 84.71% (prev 85.33%)
Tobins Q-Ratio = 4.30 (Enterprise Value 141b / Total Assets 32.7b)
Interest Expense / Debt = 0.16% (Interest Expense 13.3m / Debt 8.46b)
Taxrate = 16.46% (783.2m / 4.76b)
NOPAT = 4.01b (EBIT 4.80b * (1 - 16.46%))
Current Ratio = 2.34 (Total Current Assets 11.7b / Total Current Liabilities 5.00b)
Debt / Equity = 0.40 (Debt 8.46b / totalStockholderEquity, last quarter 20.9b)
Debt / EBITDA = 0.43 (Net Debt 2.16b / EBITDA 5.04b)
Debt / FCF = 0.67 (Net Debt 2.16b / FCF TTM 3.20b)
Total Stockholder Equity = 19.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.81% (Net Income 3.98b / Total Assets 32.7b)
RoE = 20.08% (Net Income TTM 3.98b / Total Stockholder Equity 19.8b)
RoCE = 20.60% (EBIT 4.80b / Capital Employed (Equity 19.8b + L.T.Debt 3.50b))
RoIC = 14.27% (NOPAT 4.01b / Invested Capital 28.1b)
WACC = 5.99% (E(139b)/V(147b) * Re(6.35%) + D(8.46b)/V(147b) * Rd(0.16%) * (1-Tc(0.16)))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.47 | Cagr: -0.50%
[DCF] Terminal Value 74.88% ; FCFF base≈3.26b ; Y1≈3.16b ; Y5≈3.12b
[DCF] Fair Price = 184.6 (EV 49.0b - Net Debt 2.16b = Equity 46.8b / Shares 253.5m; r=8.35% [WACC [floored]]; 5y FCF grow -4.04% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.81 | # QB: 0
Revenue Correlation: 99.85 | Revenue CAGR: 10.27% | SUE: -0.77 | # QB: 0
EPS current Quarter (2027-03-31): EPS=4.78 | Chg30d=+3.49% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=18.12 | Chg30d=+5.70% | Revisions=+44% | GrowthEPS=-1.5% | GrowthRev=+10.5%
EPS next Year (2027-12-31): EPS=19.95 | Chg30d=-1.33% | Revisions=+30% | GrowthEPS=+10.1% | GrowthRev=+10.5%
[Analyst] Revisions Ratio: +44% (up=10, down=3)